Under the leadership of the Türk Tıbbi Onkoloji Derneği – Turkish Society of Medical Oncology, the “Consensus Report on Immunotherapy Treatments in Non-Small Cell Lung Cancer (NSCLC),” with the unconditional support of Bristol Myers Squibb Türkiye, has been published.
This report, aiming for the more effective and accessible use of immunotherapy for NSCLC patients, presents the latest scientific data on immunotherapy studies with expert opinions.
Published in the Journal of Oncological Sciences and prepared in collaboration with various associations under the leadership of the Turkish Society of Medical Oncology, this report was announced at the Cancer Immunotherapy Society’s Congress on Immuno-Oncological and Molecular Oncological Treatments on November 25, 2023.
Prof. Dr. Nuri Karadurmuş from the Turkish Society of Medical Oncology and Prof. Dr. Erdem Göker from the Turkish Lung Cancer Association explain the reasons for the preparation of the consensus report as follows: “Every year, thousands of people in Türkiye are diagnosed with lung cancer. The diagnosis of these cases is often noticed in the advanced stages, leading to unfortunate outcomes. Existing treatment methods, such as surgery, radiation, and chemotherapy, may not be very effective in treating patients in these advanced stages. This has created the need to develop new therapeutic strategies, such as immunotherapy. However, the current options for immunotherapy may have limited long-term effectiveness in cancer treatment. Therefore, our clinical research studies on effective immunotherapy agents are ongoing.”
